Eledon Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ELDN$2.61+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Eledon Pharmaceuticals, Inc. | ||
| Date: November 12, 2024 | By: | /s/ David-Alexandre C. Gros, M.D. |
|---|---|---|
| David-Alexandre C. Gros, M.D. | ||
| Chief Executive Officer and Director (PrincipalExecutive Officer) | ||
| Date: November 12, 2024 | By: | /s/ Paul Little |
|---|---|---|
| Paul Little | ||
| Chief Financial Officer (Principal Financial and Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.